Toxicities of Targeted Therapy and Their Management in Kidney Cancer

Di Lorenzo G., Porta C., Bellmunt J., Sternberg C., Kirkali Z., Staehler M., ...Daha Fazla

EUROPEAN UROLOGY, cilt.59, sa.4, ss.526-540, 2011 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 59 Sayı: 4
  • Basım Tarihi: 2011
  • Doi Numarası: 10.1016/j.eururo.2011.01.002
  • Dergi Adı: EUROPEAN UROLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.526-540
  • Anahtar Kelimeler: Metastatic renal cell cancer, Targeted agents, Toxicity
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Context: The therapeutic scenario for metastatic renal cell carcinoma (mRCC) has been evolving rapidly, with sunitinib, sorafenib, bevacizumab, everolimus, pazopanib, and temsirolimus being successfully tested and approved in a short period of time. Oncologists must be familiar with the management of toxicity that these biologic agents cause, as such toxicity is different from that of conventional chemotherapeutic agents.